NCT00911066 2013-12-05MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic LeukemiaMillennium Pharmaceuticals, Inc.Phase 1 Completed72 enrolled